- Home
- Ophthalmology
- Ianalumab for Sjogren’s Syndrome: 52 Week Results from a Randomised, Placebo-Controlled, Phase 2b Dose-Ranging Trial

20223 min read
Medical Article
Lymphocytic leakage from some exocrine glands of the body and B-cell hyperactivity leads to the development of Sjogren’s syndrome. (1,2). It is an autoimmune, progressive, systemic disease characterised by pain, fatigue, and mucosal dryness, with a risk of systemic complications (joints, lungs, skin, and peripheral nerves being the most frequently

Ianalumab for Sjogren’s Syndrome: 52 Week Results from a Randomised, Placebo-Controlled, Phase 2b Dose-Ranging Trial
Similar Content

Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments

Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes

Switching from Premixed Insulin to Basal Insulin with OADs
1083 Reached2 Comments6 Likes

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Farmer with Pain, Redness, Watering and Reduced Vision in the Right Eye
2466 Reached5 Comments7 Likes